Oncolytics Biotech Inc. (ONCY)
| Market Cap | 58.95M -46.0% |
| Revenue (ttm) | n/a |
| Net Income | -37.46M |
| EPS | -0.34 |
| Shares Out | 127.51M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 859,328 |
| Open | 0.4703 |
| Previous Close | 0.4732 |
| Day's Range | 0.4601 - 0.4998 |
| 52-Week Range | 0.4414 - 1.3200 |
| Beta | 1.16 |
| Analysts | Buy |
| Price Target | 4.16 (+799.85%) |
| Est. Earnings | Nov 11, 2026 |
About ONCY
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of gastrointestinal (“GI”) tumors, metastatic colorectal cancer, anal cancer, and metastatic pancreatic cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies. Oncolytics Biotech Inc. was incorporated ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for ONCY stock is "Buy." The 12-month stock price target is $4.16, which is an increase of 799.85% from the latest price.
News
Oncolytics reports updated data from Cohort 4 of Phase 1/2 GOBLET studt
Oncolytics (ONCY) Biotech announced updated data from Cohort 4 of its Phase 1/2 GOBLET study evaluating pelareorep in combination with atezolizumab in patients with second-line or later squamous cell ...
Oncolytics Biotech® Reports Strong Durability and Survival Data in Anal Cancer, Positioning Pelareorep as Potential Backbone Immunotherapy Across HPV-Driven Cancers
Oncolytics announced durability and survival data in anal cancer from GOBLET study, with 100% of responding patients survived for longer than one year.
Oncolytics to present REO 033 trial in progress abstract at ESMO
Oncolytics (ONCY) Biotech is presenting a trial-in-progress abstract and e-poster discussing the REO 033 study at the European Society for Medical Oncology Congress 2026. REO 033 is a randomized study...
Oncolytics Biotech® to Present REO 033 Trial in Progress Abstract at ESMO Showcasing Pelareorep's Potential in Colorectal Cancer
SAN DIEGO, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today announced the ...
Oncolytics Biotech® Provides Update on GOBLET Study Clinical Data and Final PanCAN Grant Payment
Completion of enrollment earlier this year and expected final PanCAN grant payment this quarter mark successful completion of a key phase of Cohort 5 Final Cohort 4 results expected in Q4 2026; initia...
Oncolytics should be bought amid recent weakness, says Lake Street
Lake Street analyst Chad Messer notes Oncolytics (ONCY) reported that a new method of use patent covering pelareorep as an immunotherapy for the treatment of cancer has been issued in…
Oncolytics provides intellectual property portfolio update
Oncolytics (ONCY) provided an update on its intellectual property strategy, outlining progress on new method of use patents and plans to expand its portfolio with composition of matter protection for…
Oncolytics Biotech® Secures Patent Protection to Late 2040s and Provides Intellectual Property Portfolio Update
New method of use patent covering pelareorep as an immunotherapy for cancer has been issued in several countries, with U.S. issuance expected in the near term Three patent applications are pending, in...
Oncolytics Biotech Proxy statement: Proxy filing
Oncolytics Biotech filed a proxy statement on October 6, 2026, providing details for shareholder voting and corporate governance matters.
Oncolytics Biotech Proxy statement: Proxy filing
Oncolytics Biotech filed a proxy statement on October 6, 2026, providing details for shareholder voting and corporate governance matters.
Oncolytics announces publication of data on pelareorep in liver cancer
Oncolytics (ONCY) Biotech announced data published in the Proceedings of the National Academy of Sciences show pelareorep’s ability to change an immunologically inactive liver cancer tumor microenviro...
Oncolytics Biotech® Announces Publication Demonstrating Pelareorep Creates Immune Responses in Liver Cancer That Make Tumors Susceptible to Immunotherapy
SAN DIEGO, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today announced dat...
Oncolytics reports accelerating enrollment in REO 033 study
Oncolytics (ONCY) Biotech announced continued clinical and operational progress in REO 033, its randomized study evaluating pelareorep in second-line RAS-mutant, microsatellite-stable metastatic color...
Oncolytics Biotech® Reports Accelerating Enrollment in Randomized REO 033 RAS-Mutant, MSS Colorectal Cancer Study
Substantially all planned REO 033 clinical sites are now activated, with multiple patients currently on study Company expects to have sufficient Part A data to provide an interim clinical update by ye...
Oncolytics reports pelareorep preclinical results
Oncolytics (ONCY) announced preclinical results evaluating pelareorep in combination with a pan-RAS inhibitor in a RAS-driven colorectal cancer model. During the initial treatment period, when pelareo...
Oncolytics Biotech® Announces Positive Preclinical Results Combining Pelareorep with a Pan-RAS Inhibitor in Colorectal Cancer
Oncolytics announced positive preclinical results evaluating pelareorep in combination with a pan-RAS inhibitor in a RAS-driven colorectal cancer model.
Oncolytics price target lowered to $5 from $10 at H.C. Wainwright
H.C. Wainwright analyst Patrick Trucchio lowered the firm’s price target on Oncolytics (ONCY) to $5 from $10 and keeps a Buy rating on the shares. The firm updated the company’s…
Oncolytics aligns with FDA on path for REO 033 expansion study
Oncolytics (ONCY) announced that it has received written feedback from the FDA regarding the design of a potential pivotal Part B expansion of REO 033, the company’s ongoing randomized study…
Oncolytics Biotech® Aligns with FDA on Registrational Path for Second-Line RAS-Mutant MSS Colorectal Cancer
FDA written feedback provides alignment on a potential pivotal Part B expansion of the ongoing REO 033 study Proposed pathway offers potential accelerated approval based on objective response rate and...
Oncolytics Biotech Quarterly report: Q2 2026
Oncolytics Biotech has published its Q2 2026 quarterly earnings report on August 12, 2026.
Oncolytics announces FDA Fast Track designation for pelareorep
Oncolytics (ONCY) announced that the FDA has granted Fast Track designation to pelareorep in combination with a checkpoint inhibitor for the treatment of patients with inoperable, locally recurrent or...
Oncolytics Biotech® Receives Fast Track Designation for Pelareorep in Second-Line and Later Anal Cancer
Designation supports development in an estimated $1 billion market where there are no FDA-approved therapies for patients whose disease progresses following first-line standard of care therapy Third F...
Oncolytics provides clinical, regulatory update on REO 033
Oncolytics (ONCY) provided a clinical and regulatory update on REO 033, the company’s randomized controlled study evaluating pelareorep in combination with folinic acid, fluorouracil and irinotecan an...
Oncolytics Biotech® Reports FDA Regulatory Milestone and Strong Clinical Progress in Randomized RAS-Mutant MSS Colorectal Cancer Trial
Half of planned clinical sites will be activated this month; more than 20 patients have been pre-identified across participating centers Company to hold Type D meeting with FDA to discuss a potential ...
Oncolytics secures new patent for pelareorep manufacturing
Oncolytics (ONCY) Biotech announced that the United States Patent and Trademark Office has issued a new patent protecting its proprietary manufacturing process for pelareorep. The newly issued patent ...